OXON Epidemiology at the 21st Global CVCT Forum
December 9-11, 2024 | Washington, DC
OXON Epidemiology will be participating in the 21st Global CardioVascular Clinical Trialists Forum (CVCT), taking place in Washington, DC, from December 9 to December 11, 2024. This prestigious forum brings together global leaders in cardiovascular research, regulatory authorities, and industry experts to explore advancements and challenges in clinical trials.
The CVCT Forum provides a unique opportunity for experts to collaborate and share insights that shape the future of cardiovascular care.
Representing OXON Epidemiology, Dr. Nawab Qizilbash, Chief Medical Officer, will engage with distinguished professionals in meaningful discussions aimed at improving cardiovascular health globally.
Key Sessions Led by Dr. Nawab Qizilbash
December 9 | 8:00 – 10:30 AM
Topic: Safety Evaluation of Cardiovascular Drugs and Devices
December 11 | 8:00 – 10:30 AM
Topic: The Global Burden of Cardiovascular Disease and Regulatory Inclusiveness
Chaired by: FDA Commissioner Robert Califf
OXON Epidemiology’s Expertise in Cardiovascular Research
OXON Epidemiology is a full-service, European-based Contract Research Organization (CRO) conducting Real-World Evidence (RWE) studies and RWE-driven clinical trials globally. With a focus on cardiovascular, renal, metabolic (CVRM), and orphan disease therapy areas, we bring unmatched expertise to clinical research.
We work closely with leading academic figures, including Professor Stuart Pocock, to ensure our studies are are scientifically rigorous, impactful, and provide evidence-based solutions that are practical for real-world clinical care.